NovoCure News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.07.23	NVCR NOTICE: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
27.07.23	Novocure Reports Second Quarter 2023 Financial Results (Businesswire)
21.07.23	Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer (Businesswire)
18.07.23	ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
08.07.23	ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
03.07.23	Novocure to Report Second Quarter 2023 Financial Results (Businesswire)
01.07.23	ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages NovoCure Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
24.06.23	ROSEN, LEADING TRIAL ATTORNEYS, Encourages NovoCure Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
01.06.23	Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education (Businesswire)
04.05.23	Novocure Reports First Quarter 2023 Financial Results (Businesswire)
26.04.23	Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Businesswire)
14.04.23	Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023 (Businesswire)
03.04.23	Novocure to Report First Quarter 2023 Financial Results (Businesswire)
29.03.23	Kristin Stafford Joins Novocure Board of Directors (Businesswire)
16.03.23	Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program (Businesswire)
01.03.23	Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France (Businesswire)
01.03.23	Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer (Businesswire)
23.02.23	Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update (Businesswire)
23.02.23	Allyson J. Ocean, M.D., Joins Novocure Board of Directors (Businesswire)
15.02.23	Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer (Businesswire)
19.01.23	Novocure Announces Organizational Changes to Prepare for Future Growth (Businesswire)
10.01.23	Novocure: LUNAR-Studie erreicht primären Endpunkt für Gesamtüberleben bei nicht kleinzelligem Lungenkrebs (Businesswire)
09.01.23	Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update (Businesswire)
05.01.23	Zai Lab And Novocure Announce LUNAR Study Meets Primary Endpoint (RTTNews)
05.01.23	Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint (Businesswire)
27.12.22	Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
29.11.22	Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma (Businesswire)
23.11.22	Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference (Businesswire)
17.11.22	Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting (Businesswire)
15.11.22	Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada (Businesswire)
11.11.22	Novocure Secures CE Mark for New Array (Businesswire)
27.10.22	Novocure Reports Third Quarter 2022 Financial Results (Businesswire)
22.10.22	Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting (Businesswire)
20.10.22	Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology (Businesswire)
20.10.22	Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy (Businesswire)
03.10.22	Novocure to Report Third Quarter 2022 Financial Results (Businesswire)
21.09.22	Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business (Businesswire)
31.08.22	Novocure to Participate in Upcoming Investor Conferences (Businesswire)
10.08.22	Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility (Businesswire)
29.07.22	Alnylam Q2 Loss Widens, SGEN Boosts Revenue Outlook, NVCR To Report LUNAR Study Data In Q1 (RTTNews)
28.07.22	Novocure Reports Second Quarter 2022 Financial Results (Businesswire)
27.07.22	Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program (Businesswire)
01.07.22	Novocure to Report Second Quarter 2022 Financial Results (Businesswire)
21.06.22	Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer (Businesswire)
03.06.22	Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer (Businesswire)
26.05.22	Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma (Businesswire)
29.04.22	ACCD Guides Q1 Well Below Analysts' Estimates, ALNY Cuts Outlook, NVCR Braces For Busy Year (RTTNews)
28.04.22	Novocure Reports First Quarter 2022 Financial Results (Businesswire)
19.04.22	Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu (Businesswire)
08.04.22	Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lonza Grp	548.20	4.94 %	K V
CieFinRichemont	135.60	1.46 %	K V
UBS Group	28.62	1.13 %	K V
Holcim	90.18	1.08 %	K V
Alcon	76.56	0.63 %	K V
Swiss Re	127.80	-0.31 %	K V
Sika	230.60	-0.60 %	K V
Swiss Life Hldg	687.20	-0.66 %	K V
Part Grp Hldg	1’284.50	-0.96 %	K V
Kuehne+Nagel Int	205.00	-2.80 %	K V

Nachrichten zu NovoCure Limited

Aktien Top/Flop

Meistgelesene Nachrichten